In this regard, we carried out the present study to evaluate the effects of two first-line therapies, namely the mLSG15 or mLSG15-L (mLSG15/-L) and CHOP or CHOP-L (CHOP/-L) regimens, on NK cell number and activity in newly diagnosed ATL and PTCL patients. The gene discussed is DDIT3; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.